Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Levin

Showing results (151-160 of 217) with videos related to

Pageof 22
Sort By:
Blood Advances|October 9, 2021
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myelomaKristine A Frerichs, Monique C Minnema, Mark-David Levin, et al.
NEJM Evidence|February 6, 2024
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesArnon P Kater, Carolyn Owen, Carol Moreno, et al.
Blood|September 9, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn, et al.
Blood Advances|December 4, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUXAndrew Spencer, Philippe Moreau, Maria-Victoria Mateos, et al.
Blood Cancer Journal|March 16, 2022
Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the NetherlandsMirian Brink, Monique C Minnema, Otto Visser, et al.
Blood|May 12, 2019
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8<sup>+</sup> T cells and impede CAR T-cell efficacyJaco A C van Bruggen, Anne W J Martens, Joseph A Fraietta, et al.
Blood Advances|December 22, 2020
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trialRowan Kuiper, Sonja Zweegman, Mark van Duin, et al.
Blood Advances|March 27, 2026
FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA TrialJamet Bastien, Shamimeh Ahrari, Sonja Zweegman, et al.
Blood|October 7, 2020
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemiaCarsten U Niemann, Mark-David Levin, Julie Dubois, et al.
Blood Advances|September 12, 2019
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatmentIris de Weerdt, Tom Hofland, Renate de Boer, et al.
Pageof 22

Showing results (151-160 of 217) with videos related to

Sort By:
Pageof 22
Blood Advances|October 9, 2021
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myelomaKristine A Frerichs, Monique C Minnema, Mark-David Levin, et al.
NEJM Evidence|February 6, 2024
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesArnon P Kater, Carolyn Owen, Carol Moreno, et al.
Blood|September 9, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn, et al.
Blood Advances|December 4, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUXAndrew Spencer, Philippe Moreau, Maria-Victoria Mateos, et al.
Blood Cancer Journal|March 16, 2022
Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the NetherlandsMirian Brink, Monique C Minnema, Otto Visser, et al.
Blood|May 12, 2019
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8<sup>+</sup> T cells and impede CAR T-cell efficacyJaco A C van Bruggen, Anne W J Martens, Joseph A Fraietta, et al.
Blood Advances|December 22, 2020
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trialRowan Kuiper, Sonja Zweegman, Mark van Duin, et al.
Blood Advances|March 27, 2026
FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA TrialJamet Bastien, Shamimeh Ahrari, Sonja Zweegman, et al.
Blood|October 7, 2020
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemiaCarsten U Niemann, Mark-David Levin, Julie Dubois, et al.
Blood Advances|September 12, 2019
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatmentIris de Weerdt, Tom Hofland, Renate de Boer, et al.
Pageof 22